Association of low body surface area with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis: a pilot study.
discontinuation
dose reduction
idiopathic pulmonary fibrosis
nintedanib
surface area
Journal
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
ISSN: 2532-179X
Titre abrégé: Sarcoidosis Vasc Diffuse Lung Dis
Pays: Italy
ID NLM: 9610928
Informations de publication
Date de publication:
2019
2019
Historique:
received:
12
03
2018
accepted:
19
09
2018
entrez:
2
6
2020
pubmed:
1
1
2019
medline:
1
7
2020
Statut:
ppublish
Résumé
We have often encountered adverse events requiring dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis. The objectives of this study were to clarify the incidence of dose reduction and/or discontinuation following the commercialization of nintedanib and to investigate predictors of dose reduction and/or discontinuation of nintedanib at our hospital. We retrospectively identified 25 patients who had received nintedanib 150 mg twice daily at Sendai Kousei Hospital and categorized them into two groups according to whether they had or had not required dose reduction and/or discontinuation and sought to identify predictors of dose reduction and/or discontinuation. Seventeen patients developed adverse events, which included diarrhea (n=10, 44%), hepatotoxicity (n=7, 28%), and anorexia (n=2, 16%). No adverse event-related deaths occurred during the study period. Patients who required dose reduction and/or discontinuation were significantly older than those who did not (72 years vs 67 years; A low BSA was associated with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis. Further studies in larger patient samples are needed to validate these findings.
Sections du résumé
BACKGROUND
BACKGROUND
We have often encountered adverse events requiring dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis.
OBJECTIVES
OBJECTIVE
The objectives of this study were to clarify the incidence of dose reduction and/or discontinuation following the commercialization of nintedanib and to investigate predictors of dose reduction and/or discontinuation of nintedanib at our hospital.
METHODS
METHODS
We retrospectively identified 25 patients who had received nintedanib 150 mg twice daily at Sendai Kousei Hospital and categorized them into two groups according to whether they had or had not required dose reduction and/or discontinuation and sought to identify predictors of dose reduction and/or discontinuation.
RESULTS
RESULTS
Seventeen patients developed adverse events, which included diarrhea (n=10, 44%), hepatotoxicity (n=7, 28%), and anorexia (n=2, 16%). No adverse event-related deaths occurred during the study period. Patients who required dose reduction and/or discontinuation were significantly older than those who did not (72 years vs 67 years;
CONCLUSIONS
CONCLUSIONS
A low BSA was associated with dose reduction and/or discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis. Further studies in larger patient samples are needed to validate these findings.
Identifiants
pubmed: 32476938
doi: 10.36141/svdld.v36i1.7383
pii: SVDLD-36-74
pmc: PMC7247110
doi:
Substances chimiques
Indoles
0
Protein Kinase Inhibitors
0
nintedanib
G6HRD2P839
Types de publication
Journal Article
Langues
eng
Pagination
74-78Informations de copyright
Copyright: © 2019.
Références
Respir Res. 2015 Sep 24;16:116
pubmed: 26400368
Am J Respir Crit Care Med. 2010 Apr 15;181(8):832-7
pubmed: 20056903
Sci Rep. 2017 Sep 7;7(1):10811
pubmed: 28883482
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824
pubmed: 21471066
J Pharmacol Exp Ther. 2014 May;349(2):209-20
pubmed: 24556663
Eur Respir J. 2005 Aug;26(2):319-38
pubmed: 16055882
N Engl J Med. 2011 Sep 22;365(12):1079-87
pubmed: 21992121
Cancer Res. 2008 Jun 15;68(12):4774-82
pubmed: 18559524
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Eur Respir Rev. 2012 Dec 1;21(126):355-61
pubmed: 23204124